The predicted BBB penetration (QPlogBB) values indicated that VERMOD-33 (0.273) has the highest potential for CNS access, which is desirable for BACE1 inhibition in Alzheimer’s disease therapy. This evidence concerns the gene BACE1 and early-onset autosomal dominant Alzheimer disease.